MAIA BiotechnologyMAIA
Market Cap: $68.1M
About: MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.
Employees: 13
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
300% more capital invested
Capital invested by funds: $1.52M [Q1] → $6.09M (+$4.57M) [Q2]
125% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 4
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
5% more funds holding
Funds holding: 20 [Q1] → 21 (+1) [Q2]
4.83% more ownership
Funds ownership: 3.36% [Q1] → 8.19% (+4.83%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for MAIA.